A new study led by researchers at the University of Glasgow presents compelling evidence of PODS ability to elevate organoid-based therapies to a new level.
Isolating EVs in a form compatible with downstream next-generation sequencing (NGS), particularly for small RNA analysis, can be technically challenging. But using the right kits to process the samples, many different groups have now developed an efficient workflow that is generating valuable EV microRNA data.
We explore the status of CAR T-cell therapy in the treatment of solid tumors, possible causes of failure, potential solutions, and the progress of CAR T-cell therapy for solid tumors and discuss the possible significance of CAR T-cell therapy for cancer treatment in the future.
CAR-T has been revolutionary, but as an autologous therapy, it is slow and costly. Allogeneic CAR-T cells, known as iNKTS, are now in development and may offer a rapid, cheaper (and perhaps more effective) off-the-shelf solution.
Targeted protein degradation (TPD) is an emerging technique used to study cellular processes and develop new therapies. Introduced in 1999, TPD works by breaking down specific proteins using either the proteasomal or lysosomal pathways. Most current TPD methods, such as PROTACs, molecular glues, Trim-Away, and SNIPERs, depend on the ubiquitin-proteasome system (UPS) and are primarily designed to target proteins inside cells.
